Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2-positive metastatic bladder cancer

Journal of Clinical Oncology

Volumn 35, Issue 1, 2017, Pages 48-55

  Powles, Thomas ^a   Huddart, Robert A ^c   Elliott, Tony ^d   Sarker, Shah Jalal ^a   Ackerman, Charlotte ^a   Jones, Robert ^e   Hussain, Syed ^f   Crabb, Simon ^g   Jagdev, Satinder ^h   Chester, John ⁱ   Hilman, Serena ^j   Beresford, Mark ^k   Macdonald, Graham ^l   Santhanam, Sundar ^m   Frew, John A ⁿ   Stockdale, Andrew ^o   Hughes, Simon ^b   Berney, Daniel ^a   Chowdhury, Simon ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

^g UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^h ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

ⁱ CARDIFF UNIVERSITY   (United Kingdom)

^j BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^k ROYAL UNITED HOSPITALS BATH NHS FOUNDATION TRUST   (United Kingdom)

^l ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^m NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

ⁿ Northern Centre for Cancer Care   (United Kingdom)

^o UNIVERSITY HOSPITAL COVENTRY   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PLACEBO; ANTINEOPLASTIC AGENT; CISPLATIN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERBB2 PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ANOREXIA; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SCREENING; COMORBIDITY; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INFECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; NEUROPATHY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SURVIVAL RATE; TREATMENT PLANNING; VOMITING; CARCINOMA, TRANSITIONAL CELL; CHEMISTRY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; PATHOLOGY; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SECONDARY; URINARY BLADDER NEOPLASMS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; URINARY BLADDER NEOPLASMS;

EID: 85009822157     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.66.3468     Document Type: Article

References (27)

1. De Santis M, Bellmunt J, Mead G, et al: Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 30:191-199, 2012
2. Bellmunt J, von der Maase H, Mead GM, et al: Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC in-tergroup study 30987. J Clin Oncol 30:1107-1113, 2012
3. Bellmunt J, Théodore C, Demkov T, et al: Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27:4454-4461, 2009
4. Erratum: J Clin Oncol 28:182, 2010
5. Kopparapu PK, Boorjian SA, Robinson BD, et al: Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer. Anticancer Res 33:2381-2390, 2013
6. McHugh LA, Sayan AE, Mejlvang J, et al: Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of combination chemotherapy in bladder cancer cells. Int J Oncol 34:1155-1163, 2009
7. McHugh LA, Kriajevska M, Mellon JK, et al: Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens-evidence of schedule-dependent synergy. Urology 69:390-394, 2007
8. Hussain M, Daignault S, Agarwal N, et al: A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer 120:2684-2693, 2014
9. Choueiri TK, Ross RW, Jacobus S, et al: Double-blind, randomized trial of docetaxel plus van-detanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol 30:507-512, 2012
10. Grivas PD, Daignault S, Tagawa ST, et al: Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer 120:692-701, 2014
11. Galsky MD, Hahn NM, Powles T, et al: Gemcitabine, cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer 11:175-181, 2013
12. Culine S, Sellam Z, Bouaita L, et al: Combining paclitaxel and lapatinib as second-line treatment for patients with metastatic transitional cell carcinoma: A case series. Anticancer Res 32:3949-3952, 2012
13. Kandoth C, McLellan MD, Vandin F, et al: Mutational landscape and significance across 12 major cancer types. Nature 502:333-339, 2013
14. Ding W, Tong S, Gou Y, et al: Human epidermal growth factor receptor 2: A significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups. World J Urol 33: 1951-1957, 2015
15. Tsai YS, Cheng HL, Tzai TS, et al: Clinical significance of ErbB receptor family in urothelial carcinoma of the bladder: A systematic review and meta-analysis. Adv Urol 2012:181964 2012
16. Wülfing C, Machiels JP, Richel DJ, et al: A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 115:2881-2890, 2009
17. Hussain MHA, MacVicar GR, Petrylak DP, et al: Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: Results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 25:2218-2224, 2007
18. Gårdmark T, Wester K, De la Torre M, et al: Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU Int 95:982-986, 2005
19. Jimenez RE, Hussain M, Bianco FJ Jr, et al: Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 7:2440-2447, 2001
20. Oudard S, Culine S, Vano Y, et al: Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or meta-static urothelial carcinoma overexpressing Her2. Eur J Cancer 51:45-54, 2015
21. Cameron D, Casey M, Press M, et al: A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat 112:533-543, 2008
22. Rüschoff J, Hanna W, Bilous M, et al: HER2 testing in gastric cancer: A practical approach. Mod Pathol 25:637-650, 2012
23. Choudhury NJ, Campanile A, Antic T, et al: Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations. J Clin Oncol 34:2165-2171, 2016
24. Bellmunt J, Perez Valderrama B, Font A, et al: Maintenance vinflunine post cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC): Preliminary analysis of a randomized placebo controlled phase II trial (MAJA trial)-SOGUG 2011-02. J Clin Oncol 33, 2015 (suppl; abstr 4529)
25. Chow NH, Chan SH, Tzai TS, et al: Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 7:1957-1962, 2001
26. Memon AA, Sorensen BS, Meldgaard P, et al: The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: A study in bladder cancer patients. Br J Cancer 94:1703-1709, 2006
27. Powles T, Eder JP, Fine GD, et al: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:558-562, 2014